| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 93 | 2020 | 1031 | 11.170 |
Why?
|
| Liver Cirrhosis | 105 | 2022 | 1930 | 10.820 |
Why?
|
| Antiviral Agents | 79 | 2022 | 3056 | 7.120 |
Why?
|
| Ribavirin | 48 | 2018 | 395 | 5.850 |
Why?
|
| Elasticity Imaging Techniques | 25 | 2024 | 388 | 5.350 |
Why?
|
| Hepacivirus | 55 | 2021 | 1333 | 4.620 |
Why?
|
| Fluorenes | 16 | 2017 | 157 | 4.300 |
Why?
|
| Uridine Monophosphate | 15 | 2017 | 68 | 3.510 |
Why?
|
| Hepatitis C | 32 | 2021 | 1579 | 3.450 |
Why?
|
| Benzimidazoles | 16 | 2017 | 855 | 3.220 |
Why?
|
| Thrombocytopenia | 14 | 2021 | 1171 | 2.510 |
Why?
|
| Liver Diseases | 13 | 2024 | 1296 | 2.290 |
Why?
|
| Hepatitis B, Chronic | 10 | 2022 | 403 | 2.270 |
Why?
|
| Interferon-alpha | 31 | 2015 | 918 | 2.030 |
Why?
|
| Liver | 52 | 2024 | 7502 | 1.880 |
Why?
|
| Alanine Transaminase | 17 | 2017 | 604 | 1.660 |
Why?
|
| Benzoates | 5 | 2014 | 211 | 1.630 |
Why?
|
| Hydrazines | 5 | 2014 | 224 | 1.620 |
Why?
|
| Fatty Liver | 13 | 2024 | 777 | 1.510 |
Why?
|
| Polyethylene Glycols | 27 | 2015 | 1189 | 1.410 |
Why?
|
| Cinnamates | 2 | 2021 | 59 | 1.390 |
Why?
|
| Receptors, Thrombopoietin | 6 | 2021 | 160 | 1.360 |
Why?
|
| Genotype | 32 | 2021 | 12945 | 1.330 |
Why?
|
| Hematologic Agents | 3 | 2014 | 40 | 1.310 |
Why?
|
| Carcinoma, Hepatocellular | 14 | 2021 | 2292 | 1.270 |
Why?
|
| Interleukins | 9 | 2012 | 783 | 1.210 |
Why?
|
| Interferons | 14 | 2017 | 705 | 1.180 |
Why?
|
| Postoperative Hemorrhage | 2 | 2021 | 413 | 1.070 |
Why?
|
| Liver Neoplasms | 15 | 2021 | 4313 | 1.040 |
Why?
|
| Blood Loss, Surgical | 2 | 2021 | 653 | 1.030 |
Why?
|
| Platelet Transfusion | 3 | 2021 | 294 | 1.000 |
Why?
|
| Liver Transplantation | 10 | 2017 | 2325 | 0.980 |
Why?
|
| Mucins | 15 | 2006 | 568 | 0.960 |
Why?
|
| Drug Therapy, Combination | 35 | 2018 | 6293 | 0.950 |
Why?
|
| Viral Load | 18 | 2017 | 3321 | 0.930 |
Why?
|
| Biopsy | 35 | 2021 | 6768 | 0.920 |
Why?
|
| Pyrazoles | 5 | 2014 | 1988 | 0.880 |
Why?
|
| Hypertension, Portal | 6 | 2021 | 226 | 0.860 |
Why?
|
| Thiazoles | 2 | 2021 | 1510 | 0.820 |
Why?
|
| Aspartate Aminotransferases | 11 | 2015 | 415 | 0.810 |
Why?
|
| Gallbladder | 14 | 2006 | 305 | 0.800 |
Why?
|
| RNA, Viral | 19 | 2018 | 2836 | 0.790 |
Why?
|
| Cholesterol | 18 | 2021 | 2902 | 0.770 |
Why?
|
| Hyaluronic Acid | 9 | 2013 | 482 | 0.730 |
Why?
|
| Proline | 4 | 2015 | 456 | 0.720 |
Why?
|
| Hepatitis B | 3 | 2022 | 701 | 0.710 |
Why?
|
| Esophageal and Gastric Varices | 3 | 2010 | 208 | 0.690 |
Why?
|
| Portal Pressure | 3 | 2021 | 60 | 0.660 |
Why?
|
| Gastric Mucins | 5 | 2009 | 19 | 0.650 |
Why?
|
| Recombinant Proteins | 33 | 2015 | 6520 | 0.640 |
Why?
|
| Drug Interactions | 2 | 2021 | 1414 | 0.640 |
Why?
|
| Cholelithiasis | 8 | 2006 | 407 | 0.640 |
Why?
|
| Middle Aged | 126 | 2024 | 219568 | 0.610 |
Why?
|
| Bile | 10 | 2005 | 297 | 0.600 |
Why?
|
| Humans | 236 | 2024 | 758406 | 0.600 |
Why?
|
| Hepatic Veins | 2 | 2019 | 112 | 0.600 |
Why?
|
| Imidazoles | 3 | 2018 | 1179 | 0.590 |
Why?
|
| Benzofurans | 1 | 2018 | 140 | 0.580 |
Why?
|
| Male | 150 | 2024 | 358747 | 0.560 |
Why?
|
| Vibration | 3 | 2015 | 327 | 0.560 |
Why?
|
| Hematinics | 5 | 2013 | 280 | 0.540 |
Why?
|
| Hepatitis B e Antigens | 6 | 2022 | 133 | 0.530 |
Why?
|
| Female | 149 | 2024 | 390323 | 0.530 |
Why?
|
| Oligopeptides | 4 | 2015 | 1185 | 0.530 |
Why?
|
| Drug Therapy | 1 | 2019 | 503 | 0.530 |
Why?
|
| Quinoxalines | 1 | 2018 | 297 | 0.530 |
Why?
|
| Adult | 106 | 2024 | 219935 | 0.510 |
Why?
|
| End Stage Liver Disease | 4 | 2021 | 352 | 0.500 |
Why?
|
| Silymarin | 6 | 2012 | 45 | 0.500 |
Why?
|
| Histocytochemistry | 3 | 2017 | 700 | 0.490 |
Why?
|
| Keratin-18 | 3 | 2016 | 38 | 0.490 |
Why?
|
| Disease Progression | 26 | 2022 | 13468 | 0.490 |
Why?
|
| Cost-Benefit Analysis | 7 | 2017 | 5484 | 0.480 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2014 | 787 | 0.480 |
Why?
|
| Erythropoietin | 5 | 2013 | 719 | 0.480 |
Why?
|
| Hepatitis, Viral, Human | 3 | 2015 | 141 | 0.470 |
Why?
|
| Liver Cirrhosis, Experimental | 2 | 2008 | 29 | 0.470 |
Why?
|
| Drug Administration Schedule | 9 | 2019 | 4839 | 0.470 |
Why?
|
| Chronic Disease | 13 | 2024 | 9267 | 0.470 |
Why?
|
| Hepatic Encephalopathy | 2 | 2018 | 144 | 0.460 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 754 | 0.460 |
Why?
|
| Severity of Illness Index | 24 | 2021 | 15785 | 0.460 |
Why?
|
| Nucleosides | 1 | 2014 | 131 | 0.450 |
Why?
|
| Treatment Outcome | 43 | 2022 | 64378 | 0.450 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2019 | 748 | 0.440 |
Why?
|
| Perioperative Care | 1 | 2021 | 1028 | 0.430 |
Why?
|
| Predictive Value of Tests | 17 | 2016 | 15225 | 0.420 |
Why?
|
| Hepatitis, Chronic | 2 | 2016 | 52 | 0.420 |
Why?
|
| Cystadenocarcinoma | 1 | 2012 | 54 | 0.410 |
Why?
|
| Platelet Count | 9 | 2014 | 775 | 0.410 |
Why?
|
| Nucleotides | 1 | 2014 | 450 | 0.390 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 529 | 0.380 |
Why?
|
| Point-of-Care Systems | 2 | 2024 | 1201 | 0.380 |
Why?
|
| Liver Circulation | 3 | 2008 | 159 | 0.380 |
Why?
|
| Biopsy, Needle | 6 | 2012 | 1630 | 0.360 |
Why?
|
| Aged | 59 | 2021 | 168218 | 0.360 |
Why?
|
| Clinical Enzyme Tests | 1 | 2010 | 115 | 0.360 |
Why?
|
| Gallstones | 4 | 2010 | 283 | 0.360 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2009 | 151 | 0.340 |
Why?
|
| Fibrosis | 9 | 2024 | 2038 | 0.340 |
Why?
|
| Benzazepines | 1 | 2011 | 310 | 0.330 |
Why?
|
| Liver Function Tests | 7 | 2011 | 523 | 0.320 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2010 | 94 | 0.320 |
Why?
|
| ROC Curve | 12 | 2021 | 3563 | 0.320 |
Why?
|
| Hyponatremia | 1 | 2011 | 279 | 0.320 |
Why?
|
| Basal Ganglia | 1 | 2011 | 552 | 0.310 |
Why?
|
| Carbamates | 3 | 2016 | 191 | 0.310 |
Why?
|
| Intracranial Hemorrhages | 1 | 2014 | 820 | 0.310 |
Why?
|
| Methylene Blue | 2 | 2007 | 155 | 0.310 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2015 | 75 | 0.310 |
Why?
|
| Isoindoles | 1 | 2008 | 35 | 0.310 |
Why?
|
| Viral Nonstructural Proteins | 6 | 2016 | 223 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2019 | 10748 | 0.300 |
Why?
|
| Prognosis | 18 | 2021 | 29557 | 0.300 |
Why?
|
| Anthropometry | 1 | 2012 | 1347 | 0.300 |
Why?
|
| Gastroenterology | 1 | 2014 | 571 | 0.290 |
Why?
|
| Adenosine Deaminase | 2 | 2021 | 251 | 0.290 |
Why?
|
| Anemia | 8 | 2013 | 1504 | 0.290 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 431 | 0.290 |
Why?
|
| Hemangioma | 1 | 2012 | 727 | 0.280 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2007 | 46 | 0.280 |
Why?
|
| Substance P | 1 | 2008 | 333 | 0.280 |
Why?
|
| Gastric Mucosa | 2 | 2009 | 600 | 0.270 |
Why?
|
| Sensitivity and Specificity | 15 | 2016 | 14641 | 0.270 |
Why?
|
| DNA, Viral | 4 | 2022 | 2194 | 0.270 |
Why?
|
| Administration, Oral | 7 | 2019 | 3991 | 0.270 |
Why?
|
| Health Care Costs | 3 | 2015 | 3245 | 0.260 |
Why?
|
| Confidence Intervals | 3 | 2019 | 2925 | 0.260 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 311 | 0.260 |
Why?
|
| Double-Blind Method | 19 | 2019 | 12262 | 0.260 |
Why?
|
| Schistosomiasis | 1 | 2006 | 64 | 0.260 |
Why?
|
| Crystallization | 10 | 2010 | 533 | 0.260 |
Why?
|
| Nitric Oxide Synthase | 2 | 2007 | 906 | 0.260 |
Why?
|
| Retrospective Studies | 20 | 2022 | 80168 | 0.250 |
Why?
|
| Drug Design | 1 | 2010 | 1049 | 0.240 |
Why?
|
| Endosonography | 1 | 2009 | 607 | 0.240 |
Why?
|
| Hepatitis B virus | 2 | 2022 | 520 | 0.240 |
Why?
|
| Frontal Lobe | 1 | 2011 | 1419 | 0.240 |
Why?
|
| Glycoproteins | 6 | 2009 | 2205 | 0.240 |
Why?
|
| Collagen Type III | 1 | 2005 | 91 | 0.240 |
Why?
|
| Biochemistry | 1 | 2005 | 114 | 0.240 |
Why?
|
| United States | 22 | 2022 | 72136 | 0.240 |
Why?
|
| Drug Resistance, Viral | 5 | 2016 | 860 | 0.240 |
Why?
|
| Guanine | 2 | 2017 | 278 | 0.230 |
Why?
|
| Prospective Studies | 24 | 2024 | 54137 | 0.230 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 1370 | 0.230 |
Why?
|
| Sarcina | 1 | 2023 | 10 | 0.230 |
Why?
|
| Serum | 3 | 2017 | 210 | 0.230 |
Why?
|
| Adenoma | 2 | 2012 | 2148 | 0.220 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2019 | 177 | 0.220 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2022 | 301 | 0.220 |
Why?
|
| Cohort Studies | 15 | 2018 | 41256 | 0.220 |
Why?
|
| Young Adult | 20 | 2021 | 58808 | 0.220 |
Why?
|
| Drug Combinations | 4 | 2018 | 2020 | 0.220 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1110 | 0.210 |
Why?
|
| Microspheres | 2 | 2004 | 787 | 0.210 |
Why?
|
| Aged, 80 and over | 17 | 2023 | 58683 | 0.210 |
Why?
|
| Stomach | 2 | 2023 | 694 | 0.210 |
Why?
|
| Health Services Research | 1 | 2010 | 1812 | 0.210 |
Why?
|
| Sterols | 2 | 2004 | 62 | 0.210 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 1651 | 0.210 |
Why?
|
| Benzamides | 2 | 2018 | 1368 | 0.200 |
Why?
|
| HIV Infections | 8 | 2014 | 17275 | 0.200 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 728 | 0.200 |
Why?
|
| Mass Screening | 2 | 2013 | 5427 | 0.190 |
Why?
|
| Chemokine CXCL10 | 2 | 2014 | 316 | 0.190 |
Why?
|
| Interferon Type I | 1 | 2005 | 559 | 0.190 |
Why?
|
| Kupffer Cells | 1 | 2021 | 143 | 0.190 |
Why?
|
| Bile Ducts | 2 | 2011 | 282 | 0.190 |
Why?
|
| Registries | 2 | 2016 | 8175 | 0.190 |
Why?
|
| Mitochondria, Liver | 1 | 2021 | 190 | 0.190 |
Why?
|
| Bile Duct Diseases | 1 | 2001 | 97 | 0.180 |
Why?
|
| Weight Loss | 1 | 2012 | 2671 | 0.180 |
Why?
|
| Autocrine Communication | 1 | 2021 | 169 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2021 | 10146 | 0.180 |
Why?
|
| Hepatic Stellate Cells | 2 | 2012 | 119 | 0.180 |
Why?
|
| Acetyltransferases | 1 | 2021 | 231 | 0.180 |
Why?
|
| Ascites | 3 | 2018 | 338 | 0.180 |
Why?
|
| Quantitative Trait Loci | 2 | 2010 | 2100 | 0.180 |
Why?
|
| Hemorrhage | 1 | 2012 | 3400 | 0.180 |
Why?
|
| Collagen | 5 | 2022 | 2635 | 0.180 |
Why?
|
| Cattle | 10 | 2004 | 3845 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 1797 | 0.170 |
Why?
|
| Paracrine Communication | 1 | 2021 | 276 | 0.170 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 109 | 0.170 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2021 | 127 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 2167 | 0.170 |
Why?
|
| Cell-Derived Microparticles | 2 | 2012 | 161 | 0.170 |
Why?
|
| Tooth Extraction | 1 | 2021 | 229 | 0.170 |
Why?
|
| Lectins | 4 | 2013 | 484 | 0.170 |
Why?
|
| Adipokines | 4 | 2013 | 311 | 0.160 |
Why?
|
| Risk Assessment | 8 | 2019 | 23884 | 0.160 |
Why?
|
| Focal Nodular Hyperplasia | 2 | 2012 | 29 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 851 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 1 | 2021 | 351 | 0.150 |
Why?
|
| Desmosine | 1 | 1997 | 19 | 0.150 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2017 | 20 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2018 | 36284 | 0.150 |
Why?
|
| Recurrence | 4 | 2014 | 8426 | 0.150 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2018 | 149 | 0.150 |
Why?
|
| Adenine | 2 | 2014 | 975 | 0.150 |
Why?
|
| Aging, Premature | 1 | 2018 | 44 | 0.150 |
Why?
|
| Neutropenia | 3 | 2011 | 884 | 0.150 |
Why?
|
| Cell Transplantation | 1 | 1999 | 472 | 0.150 |
Why?
|
| Procollagen | 3 | 2006 | 187 | 0.140 |
Why?
|
| Hepatitis B Virus, Woodchuck | 1 | 2017 | 6 | 0.140 |
Why?
|
| Cognition Disorders | 1 | 2011 | 3975 | 0.140 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2016 | 156 | 0.140 |
Why?
|
| Marmota | 1 | 2017 | 12 | 0.140 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 1996 | 0.140 |
Why?
|
| Radiography | 3 | 2019 | 6954 | 0.140 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2015 | 238 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 7378 | 0.140 |
Why?
|
| Crohn Disease | 3 | 1999 | 2275 | 0.140 |
Why?
|
| Anesthesia | 1 | 2008 | 1582 | 0.140 |
Why?
|
| Time Factors | 15 | 2018 | 39872 | 0.140 |
Why?
|
| Receptors, Concanavalin A | 2 | 1993 | 11 | 0.130 |
Why?
|
| Solutions | 3 | 2005 | 412 | 0.130 |
Why?
|
| Pyridines | 2 | 2018 | 2859 | 0.130 |
Why?
|
| Epoetin Alfa | 3 | 2004 | 78 | 0.130 |
Why?
|
| Viscosity | 4 | 2009 | 335 | 0.130 |
Why?
|
| Age Factors | 6 | 2016 | 18358 | 0.130 |
Why?
|
| Sigmoidoscopy | 1 | 1996 | 151 | 0.130 |
Why?
|
| Forecasting | 2 | 2019 | 2923 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2012 | 4284 | 0.130 |
Why?
|
| Concanavalin A | 2 | 1996 | 190 | 0.120 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 3709 | 0.120 |
Why?
|
| Ammonia | 1 | 2016 | 236 | 0.120 |
Why?
|
| Lipoproteins, VLDL | 1 | 2016 | 201 | 0.120 |
Why?
|
| Cholesterol, Dietary | 2 | 2005 | 223 | 0.120 |
Why?
|
| Carbon Tetrachloride | 2 | 2008 | 72 | 0.120 |
Why?
|
| Adolescent | 16 | 2021 | 87892 | 0.120 |
Why?
|
| Calcium Phosphates | 1 | 1995 | 171 | 0.120 |
Why?
|
| Boston | 5 | 2014 | 9304 | 0.120 |
Why?
|
| RNA | 3 | 2022 | 2716 | 0.120 |
Why?
|
| Patient Care Management | 2 | 2007 | 302 | 0.120 |
Why?
|
| alpha-Fetoproteins | 3 | 2011 | 222 | 0.120 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2013 | 175 | 0.120 |
Why?
|
| Aspirin | 2 | 2016 | 3131 | 0.120 |
Why?
|
| Animals | 33 | 2017 | 167768 | 0.120 |
Why?
|
| Proteomics | 1 | 2008 | 3816 | 0.120 |
Why?
|
| Diagnostic Imaging | 2 | 2008 | 3526 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 2690 | 0.110 |
Why?
|
| New Zealand | 1 | 2014 | 352 | 0.110 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 20055 | 0.110 |
Why?
|
| Liposomes | 1 | 1997 | 777 | 0.110 |
Why?
|
| Ultrasonography, Doppler | 2 | 2007 | 463 | 0.110 |
Why?
|
| Aminopeptidases | 1 | 1994 | 95 | 0.110 |
Why?
|
| Amino Acids | 2 | 1997 | 1713 | 0.110 |
Why?
|
| Waiting Lists | 2 | 2017 | 762 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 437 | 0.110 |
Why?
|
| Alprostadil | 1 | 1993 | 86 | 0.110 |
Why?
|
| Monocytes | 2 | 2021 | 2570 | 0.110 |
Why?
|
| Pyrophosphatases | 2 | 2011 | 139 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 1722 | 0.110 |
Why?
|
| Follow-Up Studies | 12 | 2018 | 39059 | 0.110 |
Why?
|
| Bilirubin | 3 | 2009 | 437 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 3 | 2012 | 1958 | 0.110 |
Why?
|
| Cryptosporidiosis | 1 | 1993 | 53 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 5 | 2009 | 2497 | 0.110 |
Why?
|
| Lamivudine | 1 | 2014 | 362 | 0.110 |
Why?
|
| Models, Economic | 1 | 2017 | 715 | 0.110 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2012 | 7 | 0.100 |
Why?
|
| Liver Abscess, Amebic | 1 | 2012 | 20 | 0.100 |
Why?
|
| Swine | 7 | 2009 | 5892 | 0.100 |
Why?
|
| alpha-Macroglobulins | 2 | 2009 | 60 | 0.100 |
Why?
|
| Echinococcosis | 1 | 2012 | 31 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 414 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2012 | 15773 | 0.100 |
Why?
|
| Cholangitis | 1 | 1993 | 113 | 0.100 |
Why?
|
| Quality of Life | 6 | 2015 | 13285 | 0.100 |
Why?
|
| Muscle Contraction | 1 | 1997 | 1197 | 0.100 |
Why?
|
| Nucleotidyltransferases | 1 | 2014 | 243 | 0.100 |
Why?
|
| Interferon-gamma | 4 | 2012 | 3156 | 0.100 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2011 | 57 | 0.100 |
Why?
|
| Professional Practice | 1 | 2014 | 313 | 0.100 |
Why?
|
| Europe | 2 | 2018 | 3420 | 0.100 |
Why?
|
| Reference Values | 1 | 2019 | 4919 | 0.100 |
Why?
|
| Prevalence | 6 | 2021 | 15651 | 0.100 |
Why?
|
| Scattering, Radiation | 3 | 1999 | 488 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 8945 | 0.100 |
Why?
|
| Cholestasis | 1 | 2014 | 377 | 0.100 |
Why?
|
| Elasticity | 3 | 2009 | 652 | 0.090 |
Why?
|
| Thrombopoiesis | 1 | 2013 | 164 | 0.090 |
Why?
|
| Hemoglobins | 5 | 2013 | 1519 | 0.090 |
Why?
|
| Clofazimine | 1 | 1991 | 41 | 0.090 |
Why?
|
| Sex Factors | 3 | 2016 | 10504 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 1995 | 1066 | 0.090 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 25956 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 215 | 0.090 |
Why?
|
| Leukopenia | 1 | 2011 | 211 | 0.090 |
Why?
|
| Extracellular Matrix | 3 | 2003 | 1723 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2017 | 1471 | 0.090 |
Why?
|
| Drug Users | 1 | 2012 | 134 | 0.090 |
Why?
|
| Software | 1 | 2024 | 4415 | 0.090 |
Why?
|
| Antigens, Neoplasm | 3 | 2006 | 1997 | 0.090 |
Why?
|
| Macromolecular Substances | 2 | 2005 | 1433 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 1475 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2014 | 610 | 0.090 |
Why?
|
| Injections, Subcutaneous | 3 | 2018 | 677 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2021 | 627 | 0.090 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 12096 | 0.090 |
Why?
|
| Lipase | 1 | 2012 | 324 | 0.090 |
Why?
|
| Choline | 1 | 2011 | 513 | 0.080 |
Why?
|
| Biophysical Phenomena | 3 | 2002 | 320 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 168 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2011 | 295 | 0.080 |
Why?
|
| Creatine | 1 | 2011 | 426 | 0.080 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2012 | 619 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1993 | 662 | 0.080 |
Why?
|
| Colon | 3 | 2005 | 1787 | 0.080 |
Why?
|
| Polytetrafluoroethylene | 1 | 2010 | 245 | 0.080 |
Why?
|
| Aspartic Acid | 1 | 2011 | 576 | 0.080 |
Why?
|
| Biophysics | 3 | 2002 | 380 | 0.080 |
Why?
|
| Peptide Fragments | 5 | 2006 | 5098 | 0.080 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 163 | 0.080 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 624 | 0.080 |
Why?
|
| Killer Cells, Natural | 2 | 2011 | 2201 | 0.080 |
Why?
|
| Hepatitis C Antibodies | 1 | 2009 | 145 | 0.080 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2009 | 144 | 0.080 |
Why?
|
| Molecular Weight | 2 | 2005 | 2185 | 0.080 |
Why?
|
| Uncertainty | 1 | 2013 | 751 | 0.080 |
Why?
|
| Patient Admission | 1 | 2016 | 1372 | 0.080 |
Why?
|
| Head | 1 | 2014 | 921 | 0.080 |
Why?
|
| Algorithms | 4 | 2024 | 13961 | 0.080 |
Why?
|
| Cystatins | 1 | 2008 | 55 | 0.080 |
Why?
|
| Nitric Oxide | 1 | 1997 | 2131 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2017 | 2249 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1585 | 0.070 |
Why?
|
| Pentanoic Acids | 1 | 2007 | 17 | 0.070 |
Why?
|
| Intestinal Absorption | 2 | 2004 | 400 | 0.070 |
Why?
|
| Area Under Curve | 4 | 2015 | 1632 | 0.070 |
Why?
|
| Publishing | 1 | 2015 | 833 | 0.070 |
Why?
|
| Mucus | 1 | 2009 | 342 | 0.070 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 772 | 0.070 |
Why?
|
| Splenic Artery | 1 | 2007 | 57 | 0.070 |
Why?
|
| Patient Compliance | 3 | 2013 | 2685 | 0.070 |
Why?
|
| Fluorescent Dyes | 4 | 1999 | 1897 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 1911 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 20500 | 0.070 |
Why?
|
| Triglycerides | 1 | 2015 | 2451 | 0.070 |
Why?
|
| Phase Transition | 1 | 2007 | 71 | 0.070 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2008 | 97 | 0.070 |
Why?
|
| Intestinal Polyps | 1 | 1987 | 104 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2011 | 3387 | 0.070 |
Why?
|
| Risk | 1 | 2019 | 9599 | 0.070 |
Why?
|
| Cysts | 1 | 2012 | 681 | 0.070 |
Why?
|
| Acute Disease | 3 | 2006 | 7225 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 675 | 0.070 |
Why?
|
| Colonic Diseases, Functional | 1 | 1986 | 39 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 11070 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2016 | 2640 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 7985 | 0.070 |
Why?
|
| Risk Factors | 9 | 2022 | 73809 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2004 | 681 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 529 | 0.070 |
Why?
|
| Cystatin C | 1 | 2008 | 270 | 0.070 |
Why?
|
| Renal Circulation | 1 | 2007 | 291 | 0.070 |
Why?
|
| Hepatic Artery | 1 | 2007 | 230 | 0.070 |
Why?
|
| Diffusion | 2 | 1999 | 813 | 0.070 |
Why?
|
| Sodium | 1 | 2011 | 1588 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 3 | 2009 | 2646 | 0.070 |
Why?
|
| Ubiquitin | 1 | 2011 | 837 | 0.070 |
Why?
|
| Serologic Tests | 1 | 2008 | 383 | 0.070 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 507 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 376 | 0.070 |
Why?
|
| Thrombopoietin | 1 | 2008 | 226 | 0.070 |
Why?
|
| Peptides | 3 | 1999 | 4341 | 0.060 |
Why?
|
| Prednisone | 2 | 2008 | 1565 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2269 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2010 | 733 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2007 | 778 | 0.060 |
Why?
|
| Vascular Resistance | 2 | 2007 | 930 | 0.060 |
Why?
|
| Phlebitis | 1 | 2005 | 35 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7818 | 0.060 |
Why?
|
| Sciuridae | 2 | 1997 | 78 | 0.060 |
Why?
|
| Carbohydrate Metabolism | 1 | 1986 | 262 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8530 | 0.060 |
Why?
|
| Fibrinolysis | 2 | 2001 | 332 | 0.060 |
Why?
|
| Transaminases | 1 | 2005 | 196 | 0.060 |
Why?
|
| Microscopy, Atomic Force | 1 | 2005 | 247 | 0.060 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 905 | 0.060 |
Why?
|
| Insulin Resistance | 2 | 2010 | 3941 | 0.060 |
Why?
|
| Protein Conformation | 2 | 2005 | 3966 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1993 | 1743 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2011 | 3783 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 1312 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 1998 | 1765 | 0.060 |
Why?
|
| Ileal Neoplasms | 1 | 1984 | 20 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 2 | 2005 | 580 | 0.060 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2004 | 28 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3754 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2012 | 4549 | 0.060 |
Why?
|
| Molecular Conformation | 1 | 2005 | 543 | 0.060 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2006 | 529 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2007 | 837 | 0.060 |
Why?
|
| Antioxidants | 1 | 2012 | 1662 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 12951 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 349 | 0.060 |
Why?
|
| Integrin alpha1beta1 | 1 | 2003 | 7 | 0.060 |
Why?
|
| Integrin alpha2beta1 | 1 | 2003 | 17 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2006 | 12759 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2010 | 867 | 0.060 |
Why?
|
| Iron Overload | 1 | 2006 | 240 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2021 | 255 | 0.060 |
Why?
|
| Protective Agents | 1 | 2005 | 150 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 663 | 0.060 |
Why?
|
| Growth Substances | 2 | 2003 | 768 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 2239 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2014 | 8553 | 0.060 |
Why?
|
| Interferon-beta | 1 | 2006 | 345 | 0.060 |
Why?
|
| Drug Implants | 1 | 2004 | 230 | 0.060 |
Why?
|
| Anilino Naphthalenesulfonates | 2 | 1995 | 16 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 1098 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2018 | 4373 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 1462 | 0.060 |
Why?
|
| Clostridium | 1 | 2023 | 100 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2006 | 5031 | 0.050 |
Why?
|
| Bradycardia | 1 | 1985 | 299 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2011 | 3759 | 0.050 |
Why?
|
| Microscopy, Electron | 2 | 1997 | 2557 | 0.050 |
Why?
|
| Gels | 2 | 2007 | 419 | 0.050 |
Why?
|
| Mucin-1 | 2 | 2006 | 539 | 0.050 |
Why?
|
| Mental Disorders | 2 | 2017 | 6803 | 0.050 |
Why?
|
| Viral Core Proteins | 2 | 2012 | 161 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2015 | 5952 | 0.050 |
Why?
|
| Membrane Proteins | 4 | 2012 | 7843 | 0.050 |
Why?
|
| Macrophages | 1 | 2017 | 5737 | 0.050 |
Why?
|
| Fluoresceins | 2 | 2009 | 234 | 0.050 |
Why?
|
| Glycosylation | 1 | 2005 | 1095 | 0.050 |
Why?
|
| Alkaline Phosphatase | 2 | 2019 | 865 | 0.050 |
Why?
|
| Body Weight | 2 | 2010 | 4603 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 2374 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 1659 | 0.050 |
Why?
|
| Sphingomyelins | 1 | 2002 | 103 | 0.050 |
Why?
|
| Light | 2 | 1999 | 1345 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 2 | 2003 | 392 | 0.050 |
Why?
|
| Cytokines | 4 | 2007 | 7338 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 2210 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2014 | 3047 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2005 | 673 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 1628 | 0.050 |
Why?
|
| Amino Acid Sequence | 9 | 1999 | 13447 | 0.050 |
Why?
|
| Logistic Models | 4 | 2013 | 13276 | 0.050 |
Why?
|
| Antigens, CD1 | 1 | 2004 | 439 | 0.050 |
Why?
|
| Energy Intake | 1 | 1989 | 2127 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2010 | 17768 | 0.050 |
Why?
|
| Abdominal Pain | 2 | 2005 | 1063 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2017 | 6187 | 0.050 |
Why?
|
| Health Surveys | 1 | 2011 | 4064 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 1759 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5629 | 0.050 |
Why?
|
| Actins | 2 | 2019 | 2049 | 0.050 |
Why?
|
| Analgesics | 1 | 2008 | 1064 | 0.050 |
Why?
|
| Georgia (Republic) | 1 | 2020 | 39 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11424 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11152 | 0.050 |
Why?
|
| Estradiol | 2 | 2005 | 1933 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2005 | 631 | 0.040 |
Why?
|
| Collagen Type IV | 1 | 2001 | 127 | 0.040 |
Why?
|
| Lipoproteins | 2 | 2021 | 881 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 2010 | 4624 | 0.040 |
Why?
|
| Georgia | 1 | 2020 | 190 | 0.040 |
Why?
|
| HIV | 1 | 2007 | 1581 | 0.040 |
Why?
|
| Gene Expression | 3 | 2012 | 7583 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 1984 | 433 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 4353 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 1038 | 0.040 |
Why?
|
| Inflammation | 2 | 2012 | 10718 | 0.040 |
Why?
|
| Apolipoproteins B | 1 | 2021 | 385 | 0.040 |
Why?
|
| North America | 2 | 2018 | 1276 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2004 | 1745 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 2007 | 660 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2012 | 9650 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2010 | 18119 | 0.040 |
Why?
|
| Rats | 3 | 2008 | 23679 | 0.040 |
Why?
|
| Venous Pressure | 1 | 2019 | 57 | 0.040 |
Why?
|
| Protein Binding | 3 | 2005 | 9311 | 0.040 |
Why?
|
| Alanine | 1 | 2022 | 603 | 0.040 |
Why?
|
| Laminin | 1 | 2001 | 405 | 0.040 |
Why?
|
| Patient Selection | 2 | 2018 | 4244 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 3071 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2012 | 2740 | 0.040 |
Why?
|
| Phospholipids | 1 | 2002 | 784 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2015 | 12876 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 7021 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2005 | 842 | 0.040 |
Why?
|
| Static Electricity | 1 | 1999 | 261 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 1034 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 3992 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 1987 | 1152 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 1716 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 2717 | 0.040 |
Why?
|
| Rats, Inbred Lew | 1 | 1999 | 1154 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2022 | 887 | 0.040 |
Why?
|
| Heart Failure | 1 | 2022 | 11593 | 0.040 |
Why?
|
| Bethanechol | 1 | 1997 | 12 | 0.040 |
Why?
|
| Polystyrenes | 1 | 1997 | 104 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2019 | 219 | 0.040 |
Why?
|
| Acrylic Resins | 1 | 1997 | 135 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2008 | 2475 | 0.040 |
Why?
|
| Muscle Tonus | 1 | 1997 | 82 | 0.040 |
Why?
|
| Rheology | 2 | 2009 | 348 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 10112 | 0.040 |
Why?
|
| Lipoprotein(a) | 1 | 2021 | 479 | 0.030 |
Why?
|
| Sigmoidoscopes | 1 | 1996 | 5 | 0.030 |
Why?
|
| Albumins | 1 | 1999 | 575 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 1997 | 117 | 0.030 |
Why?
|
| Pronase | 1 | 1996 | 30 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 8143 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1997 | 260 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1990 | 1539 | 0.030 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1985 | 973 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 829 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1998 | 1351 | 0.030 |
Why?
|
| Molecular Sequence Data | 8 | 1999 | 17617 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 1895 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2825 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2004 | 1807 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2006 | 3664 | 0.030 |
Why?
|
| Interleukin-10 | 3 | 2012 | 1174 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 1996 | 149 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2004 | 1803 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 2210 | 0.030 |
Why?
|
| Egypt | 2 | 2007 | 98 | 0.030 |
Why?
|
| Exanthema | 2 | 2011 | 504 | 0.030 |
Why?
|
| Chemical Precipitation | 1 | 1995 | 176 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1995 | 91 | 0.030 |
Why?
|
| Lipids | 2 | 2004 | 3326 | 0.030 |
Why?
|
| Endometriosis | 1 | 1984 | 874 | 0.030 |
Why?
|
| Exercise | 1 | 2012 | 5788 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 1900 | 0.030 |
Why?
|
| Energy Transfer | 1 | 1995 | 108 | 0.030 |
Why?
|
| Genes, Viral | 1 | 2016 | 649 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 2197 | 0.030 |
Why?
|
| Receptors, Lipoprotein | 1 | 1995 | 88 | 0.030 |
Why?
|
| Species Specificity | 1 | 1999 | 2417 | 0.030 |
Why?
|
| Proteins | 1 | 1990 | 6026 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1998 | 1165 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1987 | 2523 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 5331 | 0.030 |
Why?
|
| Lipid Metabolism | 2 | 2004 | 1895 | 0.030 |
Why?
|
| Physicians | 1 | 2013 | 4580 | 0.030 |
Why?
|
| Estrogen Antagonists | 2 | 2005 | 151 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1996 | 289 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2016 | 4113 | 0.030 |
Why?
|
| Phlebotomy | 1 | 2015 | 137 | 0.030 |
Why?
|
| Remission Induction | 2 | 1991 | 2388 | 0.030 |
Why?
|
| Immunochemistry | 1 | 1994 | 119 | 0.030 |
Why?
|
| Chromatography, Gel | 2 | 1996 | 645 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 1141 | 0.030 |
Why?
|
| Cysteine | 2 | 1997 | 893 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 504 | 0.030 |
Why?
|
| Cognition | 1 | 2011 | 6953 | 0.030 |
Why?
|
| Linear Models | 2 | 2016 | 5862 | 0.030 |
Why?
|
| Depression | 1 | 2013 | 8057 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2010 | 607 | 0.030 |
Why?
|
| Spleen | 1 | 1999 | 2296 | 0.030 |
Why?
|
| Crystallography | 1 | 1993 | 116 | 0.030 |
Why?
|
| Particle Size | 1 | 1997 | 1641 | 0.030 |
Why?
|
| CpG Islands | 1 | 2018 | 1221 | 0.030 |
Why?
|
| Probability | 1 | 2018 | 2467 | 0.030 |
Why?
|
| Mice | 8 | 2010 | 81101 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 142 | 0.030 |
Why?
|
| Headache | 2 | 2013 | 1248 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2007 | 8451 | 0.030 |
Why?
|
| Hypertension | 1 | 2012 | 8499 | 0.030 |
Why?
|
| Portal System | 1 | 1992 | 49 | 0.030 |
Why?
|
| Metaplasia | 1 | 1993 | 321 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 4048 | 0.030 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2011 | 27 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2011 | 35 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 373 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3801 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 1996 | 551 | 0.020 |
Why?
|
| Catheterization | 1 | 1996 | 1426 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1999 | 2378 | 0.020 |
Why?
|
| Apoptosis | 1 | 2007 | 9468 | 0.020 |
Why?
|
| Water | 1 | 1997 | 1402 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 12440 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2011 | 112 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2189 | 0.020 |
Why?
|
| Plasma | 1 | 2014 | 584 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 1945 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2006 | 3204 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 1993 | 795 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4567 | 0.020 |
Why?
|
| Prothrombin | 1 | 2011 | 190 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1996 | 1673 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 213 | 0.020 |
Why?
|
| Half-Life | 1 | 2011 | 652 | 0.020 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1990 | 126 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1990 | 297 | 0.020 |
Why?
|
| Binding Sites | 1 | 1999 | 6036 | 0.020 |
Why?
|
| Gastric Juice | 1 | 1989 | 59 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2015 | 456 | 0.020 |
Why?
|
| Obesity | 1 | 2012 | 12870 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 1993 | 638 | 0.020 |
Why?
|
| Nausea | 1 | 2013 | 677 | 0.020 |
Why?
|
| Trypsin | 1 | 1990 | 496 | 0.020 |
Why?
|
| Urease | 1 | 2009 | 39 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 23342 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3425 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 2942 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1991 | 638 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 2 | 1987 | 136 | 0.020 |
Why?
|
| Research Design | 2 | 2018 | 6157 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2012 | 616 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1995 | 1411 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1995 | 1355 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2010 | 735 | 0.020 |
Why?
|
| Viremia | 1 | 2012 | 706 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2010 | 12094 | 0.020 |
Why?
|
| Virus Replication | 1 | 2017 | 2430 | 0.020 |
Why?
|
| Models, Molecular | 1 | 1999 | 5410 | 0.020 |
Why?
|
| Fasting | 1 | 2015 | 1599 | 0.020 |
Why?
|
| Peptic Ulcer Perforation | 1 | 1988 | 22 | 0.020 |
Why?
|
| Placebos | 1 | 2013 | 1661 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 596 | 0.020 |
Why?
|
| Duodenal Ulcer | 1 | 1988 | 121 | 0.020 |
Why?
|
| Jaundice, Obstructive | 1 | 2008 | 20 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 12604 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 1 | 1988 | 157 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 746 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2018 | 22029 | 0.020 |
Why?
|
| Mucin-5B | 2 | 1998 | 147 | 0.020 |
Why?
|
| Epitopes | 1 | 1993 | 2502 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 1990 | 622 | 0.020 |
Why?
|
| Urea | 1 | 2009 | 444 | 0.020 |
Why?
|
| Safety Management | 1 | 2012 | 760 | 0.020 |
Why?
|
| California | 1 | 2011 | 1419 | 0.020 |
Why?
|
| Gallbladder Emptying | 1 | 2006 | 14 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1125 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Lactulose | 1 | 1986 | 31 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1474 | 0.020 |
Why?
|
| Glycolysis | 1 | 1990 | 826 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1430 | 0.020 |
Why?
|
| Base Sequence | 4 | 1999 | 12436 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 1197 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2021 | 6548 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2015 | 1129 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2007 | 234 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1996 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2005 | 58 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2005 | 56 | 0.020 |
Why?
|
| Hydrogen | 1 | 1986 | 171 | 0.020 |
Why?
|
| Outpatients | 1 | 2013 | 1591 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6821 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 1705 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 1996 | 5199 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6493 | 0.020 |
Why?
|
| Eating | 1 | 1992 | 1536 | 0.020 |
Why?
|
| Breath Tests | 1 | 1986 | 297 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 12075 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2018 | 6201 | 0.020 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2004 | 31 | 0.010 |
Why?
|
| Castration | 1 | 2004 | 153 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2004 | 84 | 0.010 |
Why?
|
| DNA, Complementary | 2 | 1998 | 1991 | 0.010 |
Why?
|
| Cell Movement | 3 | 2003 | 5201 | 0.010 |
Why?
|
| Riboflavin Deficiency | 1 | 1983 | 2 | 0.010 |
Why?
|
| Vitamin B 6 Deficiency | 1 | 1983 | 18 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3615 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1987 | 1705 | 0.010 |
Why?
|
| Ascorbic Acid Deficiency | 1 | 1983 | 25 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 1854 | 0.010 |
Why?
|
| Antigens, CD1d | 1 | 2004 | 217 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 9518 | 0.010 |
Why?
|
| Data Collection | 1 | 2013 | 3322 | 0.010 |
Why?
|
| Estrogen Receptor beta | 1 | 2004 | 168 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2005 | 610 | 0.010 |
Why?
|
| Thiamine Deficiency | 1 | 1983 | 48 | 0.010 |
Why?
|
| Gastrointestinal Transit | 1 | 2004 | 99 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2904 | 0.010 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 2002 | 41 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2016 | 3586 | 0.010 |
Why?
|
| Enterocytes | 1 | 2004 | 220 | 0.010 |
Why?
|
| Cell Line | 3 | 2004 | 15591 | 0.010 |
Why?
|
| Disease Management | 1 | 2013 | 2500 | 0.010 |
Why?
|
| Integrin alpha Chains | 1 | 2003 | 95 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2006 | 580 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2012 | 6354 | 0.010 |
Why?
|
| Clone Cells | 2 | 1998 | 1660 | 0.010 |
Why?
|
| Incidence | 2 | 2013 | 21272 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 2003 | 196 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2004 | 372 | 0.010 |
Why?
|
| Gastrointestinal Motility | 1 | 2004 | 234 | 0.010 |
Why?
|
| Rectum | 1 | 1987 | 895 | 0.010 |
Why?
|
| Hydrogen Bonding | 1 | 2002 | 290 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14490 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2004 | 513 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 2753 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2006 | 705 | 0.010 |
Why?
|
| Ileum | 1 | 1984 | 555 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10495 | 0.010 |
Why?
|
| Bile Acids and Salts | 1 | 2004 | 383 | 0.010 |
Why?
|
| Prisoners | 1 | 2005 | 314 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2012 | 5864 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1992 | 4159 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2004 | 585 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1989 | 1607 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1997 | 4169 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 563 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 617 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2004 | 1607 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 695 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1986 | 1207 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 5816 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2004 | 1031 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2004 | 1047 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2004 | 1254 | 0.010 |
Why?
|
| TATA Box | 1 | 1998 | 127 | 0.010 |
Why?
|
| Mice, Knockout | 2 | 2004 | 14354 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 2129 | 0.010 |
Why?
|
| Viral Structural Proteins | 1 | 1998 | 95 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 6234 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1985 | 951 | 0.010 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 1780 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 2112 | 0.010 |
Why?
|
| Feces | 1 | 2004 | 1456 | 0.010 |
Why?
|
| Chymotrypsin | 1 | 1997 | 138 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2004 | 1230 | 0.010 |
Why?
|
| Genomic Library | 1 | 1997 | 189 | 0.010 |
Why?
|
| Alcoholism | 1 | 1988 | 1962 | 0.010 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 1996 | 44 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1997 | 262 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 6068 | 0.010 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 1996 | 19 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1997 | 365 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1997 | 852 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2012 | 7980 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 2004 | 1264 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1996 | 6852 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 5779 | 0.010 |
Why?
|
| Sepharose | 1 | 1996 | 105 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 2439 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 11892 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 3824 | 0.010 |
Why?
|
| Temperature | 1 | 2002 | 2219 | 0.010 |
Why?
|
| Scavenger Receptors, Class B | 1 | 1995 | 84 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1996 | 169 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 3617 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5404 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 1995 | 123 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 783 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 777 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1995 | 297 | 0.010 |
Why?
|
| Introns | 1 | 1997 | 978 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 2176 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 2816 | 0.010 |
Why?
|
| Rural Population | 1 | 2004 | 2254 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 823 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1996 | 506 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1998 | 1694 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1997 | 656 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1998 | 1955 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 3142 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 1154 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1997 | 672 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1993 | 240 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 1995 | 696 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1998 | 18940 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 886 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 29915 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1993 | 331 | 0.010 |
Why?
|
| Exons | 1 | 1997 | 2387 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 36055 | 0.010 |
Why?
|
| Veterans | 1 | 2005 | 2631 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12721 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 4938 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10416 | 0.010 |
Why?
|
| Pepstatins | 1 | 1989 | 10 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 42062 | 0.010 |
Why?
|
| Sucralfate | 1 | 1989 | 12 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1995 | 596 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1996 | 1593 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1998 | 1972 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1992 | 1486 | 0.000 |
Why?
|
| Peptic Ulcer | 1 | 1989 | 217 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1993 | 1368 | 0.000 |
Why?
|
| Ireland | 1 | 1988 | 171 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 22003 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1986 | 7403 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 4711 | 0.000 |
Why?
|
| Tranexamic Acid | 1 | 1989 | 176 | 0.000 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 16886 | 0.000 |
Why?
|
| Diet | 1 | 2004 | 8005 | 0.000 |
Why?
|
| Child | 1 | 2013 | 79818 | 0.000 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1985 | 336 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1989 | 1434 | 0.000 |
Why?
|
| Pregnancy | 1 | 2004 | 29742 | 0.000 |
Why?
|
| Brain | 1 | 2002 | 26947 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1988 | 15637 | 0.000 |
Why?
|